1 / 5

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020. According to the procurement of contrast media from sample hospitals in 16 cities, the CT contrast media with market shares ranking top 4 in China are iohexol, iopromide, ioversol and iodixanol successively, with market shares of 20.23%, 20.21%, 19.32% and 9.32% respectively.<br><br>For more information inquire @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=433770<br>

paulnelson74
Download Presentation

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. Published: Aug 2015 Single User PDF: US$ 2200 Corporate User PDF: US$ 2700 © ReportsnReports.com / Contact sales@reportsandreports.com

  2. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020 According to the procurement of contrast media from sample hospitals in 16 cities, the CT contrast media with market shares ranking top 4 in China are iohexol, iopromide, ioversol and iodixanol successively, with market shares of 20.23%, 20.21%, 19.32% and 9.32% respectively. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020. The main raw materials of contrast media in the upstream market are bulk drugs such as iohexol and barium sulfate. Iohexol segment market is small, suppliers and purchasers are relatively concentrated in this market and purchasing prices are settled by manufacturers. The main iohexol suppliers are the three, so raw material purchase of manufacturing enterprises is relatively concentrated. If bulk drug suppliers increase prices, manufacturing enterprises have difficulties to change other suppliers, so they may face risks relating to rising production cost. Therefore upstream suppliers have strong bargaining power in contrast media industry. The downstream markets of contrast media industry mainly are drug dealers or hospitals. The purchasing prices are settled by the two parties because of quantity buying or long-term buying, or customers can purchase by invitation to bid, at this time customers have relatively stronger bargaining power. Purchase a Copy of the Report @ http://www.reportsnreports.com/Purchase.aspx?name=433770 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com

  3. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020 According to the sales of enterprises, there are no big differences between Chinese contrast media market and international market. Iohexol produced by Shanghai Amersham Health (a subsidiary of GE Healthcare) and iodine by Schering Pharmaceutical Ltd.(Guangdong) occupy the most market shares, and iohexol by Yangtze River Pharmaceutical, iopamidol by Shanghai Bracco Sine Pharmaceutical Corp. Ltd and ioversol by Jiangsu Hengrui Medicine are placed on the second group, and iohexol produced by GUERBET LABS (a French company) and BEILU Pharmaceutical and megluminediatrizoate by Shanghai XudongHaipu Pharmaceutical Co., Ltd. rank third group. Their market shares of main products and proportion of their products in sampled hospitals are listed in the following: Drug Name Ranking Market Shares (%) Product proportion in Enterprises iohexol 1 20.23 Shanghai Amersham Health (GE) 46.84%; Yangtze River Pharmaceutical 32.45%; BEILU Pharmaceutical 14.53%; iopromide  2 20.21 Schering Pharmaceutical (Guangzhou)100% ioversol 3 19.32 America Mallinckrodt Inc. and Canada Tyco Healthcare (33%)；Jiang Su HengRui Medicine Co., Ltd (66.26%) iopamidol 4 11.08 Shanghai Bracco Sine Pharmaceutical ( 31%); Bracco SPA (69%); Gadopentetatedimeglumine 5 10.19 Schering Pharmaceutical (Guangzhou) 38.55 %, Beijing BEILU  Pharmaceutical 34.87%, Consun Pharmaceutical Group 20.25% and Shanghai XudongHaipu Pharmaceutical  5.92 %; iodixanol 6 9.32 Shanghai XudongHaipu Pharmaceutical  63%; Inquire for this report @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=433770 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com

  4. Gadopentetatedimeglumine 1 82.84 Schering Pharmaceutical Ltd.(Guangdong) 38.55 %; BEILU Pharmaceutical 34.87; Consun Pharmaceutical Group Limited 20.25%; Shanghai XudongHaipu Pharmaceutical 5.92 %; Gadodiamide 2 15.34 GE Healthcare100% gadobenatedimeglumine 3 0.94 Shanghai Bracco Sine Pharmaceutical 11%; BRACCO(IT) 89% Gadopentetatemeglumine 4 0.88 GUERBET LABS.(FR)100% Source: Huidian Research; Sampled Hospitals’ Drug Use Database of Chinese Pharmaceutical Association As for domestic MRI contrast media market, gadopentetatedimegulmine still plays a leading role. Schering Pharmaceutical (Guangdong) accounts for less than 40% of market shares, BEILU Pharmaceutical follows behind it after imitating the same products of Schering. GE Healthcare falls behind Schering Pharmaceutical in domestic MRI market, with only about 10% of market shares, and GE is surpassed by BEILU Pharmaceutical, Consun Pharmaceutical Group Limited follows behind GE Healthcare. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020 • Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=433770 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com

  5. Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020 Currently domestic enterprises with large market scale in contrast media field are few, foreign capital enterprises occupy more than half of Chinese market and are in a leading position; while domestic enterprises represented by Yangtze River Pharmaceutical, Jiangsu Hengrui Medicine and BEILU Pharmaceutical realized the rapid expansion and increased market shares by virtue of cost performance advantage and local academic marketing. Companies Mentioned Yangtze River Pharmaceutical Group BEILU Pharmaceutical Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. China Resources Double-crane Pharmaceutical Co., Ltd. Shanghai XudongHaipu Pharmaceutical Co., Ltd. Complete Report Available @ http://www.reportsnreports.com/reports/433770-research-and-development-forecast-of-china-contrast-media-contrast-agent-market-2015-2020.html Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com

More Related